Sygnature and Cyprotex will extend their collaborative sales and marketing initiative to provide discovery chemistry/ADME-Tox/DMPK service to accelerate their clients’ drug discovery projects into development.
Cyprotex CEO Anthony Baxter said that the quality of work has enabled both the companies to form a formidable combined offering in medicinal chemistry-driven integrated drug discovery and ADME-Tox services.
"Our experience with Sygnature over the past year has led us both to conclude that we can successfully deliver integrated drug discovery services to our customers," Baxter added.